Business Description

Medherant is a developer of transdermal drug-in-adhesive patches using a novel adhesive exclusively licensed from Bostik, targeting central nervous system and pain indications.

Rationale for Investment

Building a leader in transdermal drug formulation and delivery, developing and out-licensing its own products as well as products of external partners seeking transdermal solutions.

  • The team

    Ken Cunningham – Non-executive Chair
    John Burt – CEO